BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Spinal muscular atrophy clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for spinal muscular atrophy: 45 (22 sponsors; 6 newly posted in the last 180 days, 1 stopped in the last 180 days; 4 new-entrant sponsors). Momentum score 14.4, rank 46 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 2, Phase 2 11, Phase 3 11, Phase 4 3, N/A 16.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Biogen BIIB | 10 | NA 4, P1 2, P3 4 | 0 | 1 |
| Novartis Pharmaceuticals NVS | 7 | P4 1, P3 1, NA 4, P2 1 | 2 | 1 |
| GeneCradle Inc | 3 | P3 1, P2 2 | 0 | 2 |
| Novartis Gene Therapies NVS | 2 | P3 1, NA 1 | 0 | 0 |
| Scholar Rock, Inc. SRRK | 2 | P3 1, P2 1 | 0 | 0 |
| Biohaven Pharmaceuticals, Inc. BHVN | 1 | P3 1 | 0 | 0 |
| Celgene | 1 | P3 1 | 0 | 0 |
| ORIC Pharmaceuticals ORIC new entrant | 1 | P3 1 | 1 | 0 |
| Hoffmann-La Roche | 4 | P2 1, P4 2, NA 1 | 0 | 0 |
| Guangzhou Jiayin Biotech Ltd | 2 | EARLY_P1 1, NA 1 | 0 | 0 |
| Alcyone Therapeutics, Inc | 1 | NA 1 | 0 | 0 |
| Ambulanzpartner Soziotechnologie APST GmbH new entrant | 1 | NA 1 | 1 | 0 |
| argenx ARGX | 1 | P2 1 | 0 | 0 |
| AstraZeneca AZN | 1 | P2 1 | 0 | 0 |
| Biocad | 1 | P2 1 | 0 | 0 |
| Exir Gene Pharmed new entrant | 1 | EARLY_P1 1 | 1 | 0 |
| Gemma Biotherapeutics | 1 | P2 1 | 0 | 0 |
| Lantu Biopharma | 1 | P2 1 | 0 | 0 |
| Lanyue Biotech (Hangzhou) Co., Ltd. | 1 | P2 1 | 0 | 0 |
| MarsiBionics | 1 | NA 1 | 0 | 0 |
| Nikegen Pharmaceutical (Hangzhou) Company Limited new entrant | 1 | NA 1 | 1 | 0 |
| Synchron Medical, Inc. | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: ORIC Pharmaceuticals, Ambulanzpartner Soziotechnologie APST GmbH, Exir Gene Pharmed, Nikegen Pharmaceutical (Hangzhou) Company Limited.
Recently stopped trials
- NCT07265232 Lantu Biopharma - withdrawn: Study withdrawn prior to participant enrollment following a reassessment of the clinical development plan. Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | GeneCradle Inc | NCT05824169 Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | Spinal Muscular Atrophy | recruiting | 18 |
| 2026-12-31 est. | P3 | GeneCradle Inc | NCT06971094 Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phas | SMA - Spinal Muscular Atrophy | active not recruiting | 50 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 | P2/P3 | Hoffmann-La Roche | NCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy (SMA) | completed | 97 |
| 2026-11-01 est. | P3 | Scholar Rock, Inc. SRRK | NCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neurom | active not recruiting | 238 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "spinal muscular atrophy"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.